Medgene Labs / Vaccines for Infectious and Emerging Zoonotic Diseases
Medgene Labs, South Dakota, United States
Medgene developed a patent-pending in vitro vaccine screening system and subunit vaccine production system that leverage new USDA CVB guidelines for licensing platform technologies. These platforms will support rapid introduction of new vaccines, including initial targets of Porcine Epidemic Diarrhea Virus, Rift Valley Fever, and Epizootic Hemorrhagic Disease.
Primary Application Area: Medical Devices
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: Medgene Labs patent-pending in vitro vaccine screening system and subunit vaccine production system significantly reduces the time and cost to achieve a conditional license and introduce vaccine products to the market in response to unpredictable outbreaks of infectious and emerging zoonotic diseases.
Organization Type: Early-stage Startup (Seed)
Showcase Booth #: 742
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: Medgene Labs has exclusively licensed vaccine technologies for Rift Valley Fever from the Department of Homeland Security’s Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), hosted by Kansas State University. The Department of Homeland Security announced the development of this vaccine candidate for Rift Valley Fever in its recent newsletter. The company is working closely with the U.S. Department of Agriculture’s Agriculture Research Service (USDA-ARS), who has developed a diagnostic test that will serve as a field test for Rift Valley Fever, in addition to a companion diagnostic test for the vaccine that will differentiate infected and vaccinated animals. USDA-ARS has also funded work on a vaccine candidate for Epizootic Hemorrhagic Disease, where the company’s principals collaborated in the initial research and the company has expressed an interest in licensing the technology from USDA-ARS. The company recently initiated work with South Dakota State University on a vaccine candidate for Porcine Epidemic Diarrhea Virus where USDA-APHIS’ National Veterinary Services Laboratory (NVSL) isolated the virus based on the recent outbreak in the U.S. The company has received funding from the Centers for Disease Control and the American Tissue Culture Collection to produce antisera for the World Health Organization’s influenza kits. The company has also received a National Institutes of Health Small Business Innovation Research Phase I grant for its work to treat and prevent secondary lymphedema infections from occurring in breast cancer patients.
Primary Sources of Funding: Venture Capital
Looking for: Both Funding and Development Partners